A Phase 1 interventional study of ABBV-313 and Placebo in Healthy Volunteers, sponsored by AbbVie. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single and multiple doses of ABBV-313 in healthy adult participants.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of ABBV-313 or Placebo
Drug: ABBV-313 · Drug: Placebo
Participants will receive a single dose of ABBV-313 or Placebo
Drug: ABBV-313 · Drug: Placebo
Participants will receive a single dose of ABBV-313 or Placebo
Drug: ABBV-313 · Drug: Placebo
Participants will receive a single dose of ABBV-313 or Placebo
Drug: ABBV-313 · Drug: Placebo
Participants will receive a single dose of ABBV-313 or Placebo
Drug: ABBV-313 · Drug: Placebo
Participants will receive a single dose of ABBV-313 or Placebo
Drug: ABBV-313 · Drug: Placebo
Participants will receive multiple doses of ABBV-313 or Placebo
Drug: ABBV-313 · Drug: Placebo
Participants will receive multiple doses of ABBV-313 or Placebo
Drug: ABBV-313 · Drug: Placebo
Injection
Injection
Infusion
Infusion
Number of Participants with Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to Approximately Day 329
Maximum Observed Plasma Concentration (Cmax) of ABBV-313
Cmax of ABBV-313.
Time frame: Up to Approximately Day 329
Time to Cmax (Tmax) of ABBV-313
Tmax of ABBV-313.
Time frame: Up to Approximately Day 329
Terminal Phase Elimination Rate Constant (Beta) of ABBV-313
Beta of ABBV-313.
Time frame: Up to Approximately Day 329
Terminal Phase Elimination Half-Life (t1/2) of ABBV-313
t1/2 of ABBV-313.
Time frame: Up to Approximately Day 329
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-313
AUCt of ABBV-313.
Time frame: Up to Approximately Day 329
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Feb 2028, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.